Last reviewed · How we verify

NCT00930332

Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

Terminated Phase 1 Last updated 12 February 2024
What this trial tests

Phase 1 trial testing methadone hydrochloride in Nausea and Vomiting in 8 participants. Terminated before completion.

Timeline
17 June 2010
Primary endpoint
6 January 2012
6 January 2012

Quick facts

Lead sponsorNCIC Clinical Trials Group
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment8
Start date17 June 2010
Primary completion6 January 2012
Estimated completion6 January 2012
Sites7 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

NCIC Clinical Trials Group

Who can join

18 and older, any sex, with Nausea and Vomiting or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Methadone hydrochloride may reduce chronic neuropathic pain in patients with cancer. PURPOSE: This phase I trial is studying the side effects and best dose of methadone hydrochloride as first-line therapy in treating patients with chronic neuropathic cancer pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Nausea and Vomiting

Currently open trials in the same condition.

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00930332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing